Back to Search
Start Over
Age Effect on Treatment Responses to 0.05%, 0.025%, and 0.01% Atropine
- Source :
- Ophthalmology. 128:1180-1187
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Purpose To investigate the effect of age at treatment and other factors on treatment response to atropine in the Low-Concentration Atropine for Myopia Progression (LAMP) Study. Design Secondary analysis from a randomized trial. Participants Three hundred fifty children aged 4 to 12 years who originally were assigned to receive 0.05%, 0.025%, or 0.01% atropine or placebo once daily, and who completed 2 years of the LAMP Study, were included. In the second year, the placebo group was switched to the 0.05% atropine group. Methods Potential predictive factors for change in spherical equivalent (SE) and axial length (AL) over 2 years were evaluated by generalized estimating equations in each treatment group. Evaluated factors included age at treatment, gender, baseline refraction, parental myopia, time outdoors, diopter hours of near work, and treatment compliance. Estimated mean values and 95% confidence intervals (CIs) of change in SE and AL over 2 years also were generated. Main Outcome Measures Factors associated with SE change and AL change over 2 years were the primary outcome measures. Associated factors during the first year were secondary outcome measures. Results In 0.05%, 0.025%, and 0.01% atropine groups, younger age was the only factor associated with SE progression (coefficient of 0.14, 0.15, and 0.20, respectively) and AL elongation (coefficient of –0.10, –0.11, and –0.12, respectively) over 2 years; the younger the age, the poorer the response. At each year of age from 4 to 12 years across the treatment groups, higher-concentration atropine showed a better treatment response, following a concentration-dependent effect (Ptrend Conclusions Younger age is associated with poor treatment response to low-concentration atropine at 0.05%, 0.025%, and 0.01%. Among concentrations studied, younger children required the highest 0.05% concentration to achieve similar reduction in myopic progression as older children receiving lower concentrations.
- Subjects :
- 0303 health sciences
medicine.medical_specialty
Treatment response
Age effect
business.industry
Placebo
Confidence interval
law.invention
03 medical and health sciences
Ophthalmology
Atropine
0302 clinical medicine
Randomized controlled trial
law
Internal medicine
030221 ophthalmology & optometry
medicine
business
Generalized estimating equation
Dioptre
030304 developmental biology
medicine.drug
Subjects
Details
- ISSN :
- 01616420
- Volume :
- 128
- Database :
- OpenAIRE
- Journal :
- Ophthalmology
- Accession number :
- edsair.doi...........fa05aca27d4fa9763c6e4fbae1b2625a